Actinic keratoses;Aktinische Keratosen

Hautarzt

Volumn 67, Issue 11, 2016, Pages 867-875

  Hommel, T ^a   Szeimies, R M ^a  

^a Knappschaftskrankenhaus Recklinghausen   (Germany)

Author keywords

Field directed treatment; Keratinocytes; Lesions; Precancerous conditions; Squamous cell carcinoma

Indexed keywords

ACTINIC KERATOSIS; CANCER PREVENTION; DEMOGRAPHY; DISEASE COURSE; HUMAN; REVIEW; SQUAMOUS CELL CARCINOMA; CARCINOMA, SQUAMOUS CELL; EVIDENCE BASED MEDICINE; KERATOSIS, ACTINIC; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHOTOCHEMOTHERAPY; PROCEDURES; SKIN NEOPLASMS; SKIN SURGERY; TREATMENT OUTCOME;

CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DERMATOLOGIC SURGICAL PROCEDURES; EVIDENCE-BASED MEDICINE; HUMANS; KERATOSIS, ACTINIC; MOLECULAR TARGETED THERAPY; PHOTOCHEMOTHERAPY; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84986281581     PISSN: 00178470     EISSN: 14321173     Source Type: Journal    
DOI: 10.1007/s00105-016-3873-4     Document Type: Review

References (85)

1. Schaefer I, Augustin M, Spehr C et al (2014) Prevalence and risk factors of actinic keratoses in Germany – analysis of multisource data. J Eur Acad Dermatol Venereol 28:309–313
2. Strunk T, Szeimies RM (2014) Aktinische Keratosen. Pathogenese, Klinik und moderne Therapieoptionen. Hautarzt 65:241–252
3. Memon AA, Tomenson JA, Bothwell J et al (2000) Prevalence of solar damage and actinic keratosis in a Merseyside population. Br J Dermatol 142:1154–1159
4. Chetty P, Choi F, Mitchell T et al (2015) Primary care review of actinic keratosis and its therapeutic options: a global perspective. Dermatol Ther 5:19–35
5. Schmitt J, Seidler A, Diepgen TL et al (2011) Occupational ultraviolet light exposure increases the risk for the development of cutaneous squamous cell carcinoma: a systematic review and meta-analysis. Br J Dermatol 164:291–307
6. Oldenburg M, Kuechmeister B, Ohnemus U et al (2013) Actinic keratosis among seafarers. Arch Dermatol Res 305:787–796
7. Miligi L, Benvenuti A, Legittimo P et al (2013) Solar ultraviolet radiation risk in outdoor workers: a specific project of Tuscany region (Italy). Epidemiol Prev 37:51–59
8. Trakatelli M, Barkitzi K, Apap C (2016) Skin cancer risk in outdoor workers: a European multicenter case-control study. J Eur Acad Dermatol Venereol 30(Suppl 3):5–11
9. Diepgen TL, Brandenburg S, Aberer W et al (2014) Skin cancer induced by natural UV-radiation as an occupational disease-requirements for its notification and recognition. J Dtsch Dermatol Ges 12:1102–1106
10. Kaufmann RA, Oberholzer PA, Cazzaniga S (2016) Epithelial skin cancers after kidney transplantation: a retrospective single-centre study of 376 recipients. Eur J Dermatol 26:265–270
11. Iannacone MR, Sinnya S, Pandeya N (2016) Prevalence of skin cancer and related skin tumors in high-risk kidney and liver transplant recipients in Queensland, Australia. J Invest Dermatol 136:1382–1386
12. Ulrich C, Schmook T, Nindl I et al (2003) Cutaneous precancers in organ transplant recipients: an old enemy in a new surrounding. Br J Dermatol 149(Suppl 2):40–42
13. Zwald FO, Brown M (2011) Skin cancer in solid organ transplant recipients: advances in therapy and management: part II. Management of skin cancer in solid organ transplant recipients. J Am Acad Dermatol 65:263–279
14. Costa C, Scalvenzi M, Ayala F (2015) How to treat actinic keratosis? An update. J Dermatol Case Rep 9:29–35
15. Marks R, Foley P, Goodman G et al (1986) Spontaneous remission of solar keratoses: the case for conservative management. Br J Dermatol 115:649–655
16. Dodson JM, DeSpain J, Hewett JE et al (1991) Malignant potential of actinic keratoses and the controversy over treatment. A patient-oriented perspective. Arch Dermatol 127:1029–1031
17. Fuchs A, Marmur E (2007) The kinetics of skin cancer: progression of actinic keratosis to squamous cell carcinoma. Dermatol Surg 33:1099–1101
18. Röwert-Huber J, Patel MJ, Forschner T et al (2007) Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification. Br J Dermatol 156(Suppl 3):8–12
19. Fernandez-Figueras MT, Carrato C, Saenz X et al (2015) Actinic keratosis with atypical basal cells (AK I) is the most common lesion associated with invasive squamous cell carcinoma of the skin. J Eur Acad Dermatol Venereol 29:991–997
20. Hensen P, Müller ML, Haschemi R et al (2009) Predisposing factors of actinic keratosis in a North-West German population. Eur J Dermatol 19:345–354
21. Babilas P, Landthaler M, Szeimies RM (2003) Aktinische Keratosen. Hautarzt 546:551–562
22. Luo JL, Tong WM, Yoon JH et al (2001) UV-induced DNA damage and mutations in Hupki (human p53 knock-in) mice recapitulate p53 hotspot alterations in sun-exposed human skin. Cancer Res 61(22):8158–8163
23. Tomas D (2009) Apoptosis, UV-radiation, precancerosis and skin tumors. Acta Med Croatica 63(Suppl 2):53–58
24. Kivisaari A, Kähäri VM (2013) Squamous cell carcinoma of the skin: emerging need for novel biomarkers. World J Clin Oncol 4:85–90
25. Pierceall WE, Goldberg LH, Tainsky MA et al (1991) Ras gene mutation and amplification in human nonmelanoma skin cancers. Mol Carcinog 4:196–202
26. Ratushny V, Gober MD, Hick R et al (2012) From keratinocyte to cancer: the pathogenesis and modeling of cutaneous squamous cell carcinoma. J Clin Invest 122:464–472
27. Spencer JM, Kahn SM, Jiang W et al (1995) Activated ras genes occur in human actinic keratoses, premalignant precursors to squamous cell carcinomas. Arch Dermatol 131:796–800
28. Bamford S, Dawson E, Forbes S et al (2004) The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer 91:355–358
29. Riihilä PM, Nissinen LM, Farshchian M (2015) Complement factor I promotes progression of cutaneous squamous cell carcinoma. J Invest Dermatol 135:579–588
30. Lee CS, Bhaduri A, Mah A et al (2014) Recurrent point mutations in the kinetochore gene KNSTRN in cutaneous squamous cell carcinoma. Nat Genet 46:1060–1062
31. Nicolas M et al (2003) Notch1 functions as a tumor suppressor in mouse skin. Nat Genet 33:416–421
32. Martincorena I, Roshan A, Gerstung M (2015) Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. Science 348(6237):880–886
33. Hu B, Castillo E, Harewood L et al (2012) Multifocal epithelial tumors and field cancerization from loss of mesenchymal CSL signaling. Cell 149:1207–1220
34. Procopio MG, Csaba L, Al Labban D et al (2015) Combined CSL and p53 downregulation promotes cancer-associated fibroblast activation. Nat Cell Biol 17:1193–1204
35. Accardi R, Gheit T (2014) Cutaneous HPV and skin cancer. Presse Med 43:435–443
36. Asgari MM, Kiviat NB, Critchlow CW et al (2008) Detection of human papillomavirus DNA in cutaneous squamous cell carcinoma among immunocompetent individuals. J Invest Dermatol 128:1409–1417
37. Wang J, Aldabagh B, Yu J et al (2014) Role of human papillomavirus in cutaneous squamous cell carcinoma: a meta-analysis. J Am Acad Dermatol 70:621–629
38. Krutmann J, Berking C, Berneburg M et al (2015) New strategies in the prevention of actinic keratosis: a critical review. Skin Pharmacol Physiol 28:281–289
39. Bens G (2014) Sunscreens. Adv Exp Med Biol 810:429–463
40. Ulrich C, Jürgensen JS, Degen A et al (2009) Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. Br J Dermatol 161(Suppl 3):78–84
41. Andrews MD (2004) Cryosurgery for common skin conditions. Am Fam Physician 69:2365–2372
42. Kasuya A, Ohta I, Tokura Y et al (2015) Structural and immunological effects of skin cryoablation in a mouse model. PLOS ONE 10:e0123906
43. Nashan D, Meiss F, Müller M (2013) Therapeutic strategies for actinic keratoses – a systematic review. Eur J Dermatol 23:14–32
44. Zouboulis CC, Röhrs H (2005) Kryochirurgische Behandlung aktinischer Keratosen mit evidenzbasierter Übersicht. Hautarzt 56:353–358
45. Thai KE, Fergin P, Freeman M (2004) A prospective study of the use of cryosurgery for the treatment of actinic keratoses. Int J Dermatol 43:687–692
46. Oliveira MC (2015) Histopathological analysis of the therapeutic response to cryotherapy with liquid nitrogen in patients with multiple actinic keratosis. An Bras Dermatol 90:384–389
47. Kaufmann R, Spelman L, Weightman W et al (2008) Multicentre intraindividual randomized trial of topical methyl aminolaevulinate-photodynamic therapy vs. cryotherapy for multiple actinic keratoses on the extremities. Br J Dermatol 158:994–999
48. Szeimies RM, Karrer S, Radakovic-Fijan S et al (2002) Photodynamic therapy using topical methyl 5‑aminolevulinate compared with cryotherapy for actinic keratosis: a prospective, randomized study. J Am Acad Dermatol 47:258–262
49. Övermark M, Koskenmies S, Pitkänen S (2016) A retrospective study of treatment of squamous cell carcinoma in situ. Acta Derm Venereol 96:64–67
50. de Vries K, Prens EP (2015) Laser treatment and its implications for photodamaged skin and actinic keratosis. Curr Probl Dermatol 46:129–135
51. Wollina U, Konrad H, Karamfilov T (2001) Treatment of common warts and actinic keratoses by Er:YAG laser. J Cutan Laser Ther 3:63–66
52. Ostertag JU, Quaedvlieg PJ, Neumann MH et al (2006) Recurrence rates and long-term follow-up after laser resurfacing as a treatment for widespread actinic keratoses on the face and scalp. Dermatol Surg 32:261–267
53. Stockfleth E, Kerl H, Zwingers T et al (2011) Low-dose 5‑fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results. Br J Dermatol 165:1101–1108
54. Nguyen HP, Rivers JK (2016) Actikerall™ (5-Fluorouracil 0.5 % and Salicylic Acid 10 %) topical solution for patient-directed treatment of actinic keratoses. Skin Therapy Lett 31:1–3
55. Malvehy J, Alarcon I, Montoya J (2016) Treatment monitoring of 0.5 % 5‑fluorouracil and 10 % salicylic acid in clinical and subclinical actinic keratoses with the combination of optical coherence tomography and reflectance confocal microscopy. J Eur Acad Dermatol Venereol 30:258–265
56. Szeimies RM, Dirschka T, Prechtl A et al (2015) Efficacy of low-dose 5‑fluorouracil/salicylic acid in actinic keratoses in relation to treatment duration. J Dtsch Dermatol Ges 13:430–438
57. Hauschild A, Stockfleth E, Popp G et al (2009) Optimization of photodynamic therapy with a novel self-adhesive 5‑aminolaevulinic acid patch: results of two randomized controlled phase III studies. Br J Dermatol 160:1066–1074
58. Szeimies RM, Stockfleth E, Popp G et al (2010) Long-term follow-up of photodynamic therapy with a self-adhesive 5‑aminolaevulinic acid patch: 12 months data. Br J Dermatol 162:410–414
59. Vegter S, Tolley K (2014) A network meta-analysis of the relative efficacy of treatments for actinic keratosis of the face or scalp in Europe. PLOS ONE 9:e96829
60. Iraji F, Siadat AH, Asilian A et al (2008) The safety of diclofenac for the management and treatment of actinic keratoses. Expert Opin Drug Saf 7:167–172
61. Malvehy J, Roldán-Marín R, Iglesias-García P (2015) Monitoring treatment of field cancerisation with 3 % diclofenac sodium 2.5 % hyaluronic acid by reflectance confocal microscopy: a histologic correlation. Acta Derm Venereol 95:45–50
62. Pflugfelder A, Welter AK, Leiter U (2012) Open label randomized study comparing 3 months vs. 6 months treatment of actinic keratoses with 3 % diclofenac in 2.5 % hyaluronic acid gel: a trial of the German Dermatologic Cooperative Oncology Group. J Eur Acad Dermatol Venereol 26:48–53
63. Shergill B, Zokaie S, Carr AJ (2013) Non-adherence to topical treatments for actinic keratosis. Patient Prefer Adherence 8:35–41
64. Lebwohl M, Swanson N, Anderson LL et al (2012) Ingenol mebutate gel for actinic keratosis. N Engl J Med 11:1010–1019
65. Garbe C, Basset-Seguin N, Poulin Y et al (2016) Efficacy and safety of follow-up field treatment of actinic keratosis with ingenol mebutate 0.015 % gel: a randomized, controlled 12-month study. Br J Dermatol 3:505–513
66. Lebwohl M, Shumack S, Stein Gold L et al (2013) Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. JAMA Dermatol 1479:666–670
67. Samorano LP, Torezan LA, Sanches JA (2015) Evaluation of the tolerability and safety of a 0.015 % ingenol mebutate gel compared to 5 % 5‑fluorouracil cream for the treatment of facial actinic keratosis: a prospective randomized trial. J Eur Acad Dermatol Venereol 29:1822–1827
68. Augustin M, Tu JH, Knudsen KM (2015) Ingenol mebutate gel for actinic keratosis: the link between quality of life, treatment satisfaction, and clinical outcomes. J Am Acad Dermatol 72:816–821
69. Loven K, Stein L, Furst K et al (2002) Evaluation of the efficacy and tolerability of 0.5 % fluorouracil cream and 5 % fluorouracil cream applied to each side of the face in patients with actinic keratosis. Clin Ther 24:990–1000
70. Pomerantz H, Hogan D, Eilers D et al (2015) Long-term efficacy of topical fluorouracil cream, 5 %, for treating actinic keratosis: a randomized clinical trial. JAMA Dermatol 151:952–960
71. Krawtchenko N, Röwert-Huber J, Ulrich M et al (2007) A randomised study of topical 5 % imiquimod vs. topical 5‑fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1‑year follow-up. Br J Dermatol 157:34–40
72. Hanke CW, Beer KR, Stockfleth E et al (2010) Imiquimod 2.5 % and 3.75 % for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3‑week cycles. J Am Acad Dermatol 62:573–581
73. Stockfleth E, Sibbring GC, Alarcon I (2016) New topical treatment options for actinic keratosis: a systematic review. Acta Derm Venereol 96:17–22
74. Korman N, Moy R, Ling M et al (2005) Dosing with 5 % imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials. Arch Dermatol 141:467–473
75. Santos-Juanes J, Esteve A, Mas-Vidal A et al (2011) Acute renal failure caused by imiquimod 5 % cream in a renal transplant patient: review of the literature on side effects of imiquimod. Dermatology 222:109–112
76. Szeimies RM, Karrer S, Bäcker H (2005) Therapeutic options for epithelial skin tumors. Actinic keratoses, Bowen disease, squamous cell carcinoma, and basal cell carcinoma. Hautarzt 56:430–440
77. Szeimies RM (2015) A network meta-analysis of the relative efficacy of treatments for actinic keratosis of the face or scalp in Europe. J Eur Acad Dermatol Venereol. doi:10.1111/jdv.13206
78. Dirschka T, Radny P, Dominicus R et al (2013) Long-term (6 and 12 months) follow-up of two prospective, randomized, controlled phase III trials of photodynamic therapy with BF-200 ALA and methyl aminolaevulinate for the treatment of actinic keratosis. Br J Dermatol 168:825–836
79. Wiegell SR (2015) Update on photodynamic treatment for actinic keratosis. Curr Probl Dermatol 46:122–128
80. Szeimies RM, Torezan L, Niwa A et al (2012) Clinical, histopathological and immunohistochemical assessment of human skin field cancerization before and after photodynamic therapy. Br J Dermatol 167:150–159
81. Wiegell SR, Haedersdal M, Philipsen PA et al (2008) Continuous activation of PpIX by daylight is as effective as and less painful than conventional photodynamic therapy for actinic keratoses; a randomized, controlled, single-blinded study. Br J Dermatol 158:740–746
82. Wiegell SR, Wulf HC, Szeimies RM et al (2012) Daylight photodynamic therapy for actinic keratosis: an international consensus: International Society for Photodynamic Therapy in Dermatology. J Eur Acad Dermatol Venereol 26:673–679
83. Lacour JP, Ulrich C, Gilaberte Y et al (2015) Daylight photodynamic therapy with methyl aminolevulinate cream is effective and nearly painless in treating actinic keratoses: a randomised, investigator-blinded, controlled, phase III study throughout Europe. J Eur Acad Dermatol Venereol 29:2342–2348
84. Fargnoli MC, Piccioni A, Neri L et al (2015) Conventional vs. daylight methyl aminolevulinate photodynamic therapy for actinic keratosis of the face and scalp: an intra-patient, prospective, comparison study in Italy. J Eur Acad Dermatol Venereol 29:1926–1932
85. Szeimies RM, Lischner S, Philipp-Dormston W et al (2013) Photodynamic therapy for skin rejuvenation: treatment options - results of a consensus conference of an expert group for aesthetic photodynamic therapy. J Dtsch Dermatol Ges 11:632–636